Targeting p53 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance

Melanoma is the deadliest form of skin cancer, primarily due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may predict promising outcomes for p53 activators in melanoma therapy. Herei...

ver descrição completa

Detalhes bibliográficos
Autor principal: Loureiro, Joana B. (author)
Outros Autores: Raimundo, Liliana (author), Calheiros, Juliana (author), Carvalho, Carla (author), Barcherini, Valentina (author), Lima, Nuno R. (author), Gomes, Célia (author), Almeida, Maria Inês (author), Alves, Marco G. (author), Costa, José Luís (author), Santos, Maria M. M. (author), Saraiva, Lucília (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Melanoma
Metastasis
Drug resistance
Targeted therapy
p53
Tryptophanol-derived oxazoloisoindolinone
Texto completo:http://hdl.handle.net/1822/73358
País:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/73358

Texto Completo

http://hdl.handle.net/1822/73358

Registros relacionados